Bullous pemphigoid: From the clinic to the bench

Giovanni Di Zenzo, Rocco della Torre, Giovanna Zambruno, Luca Borradori

Research output: Contribution to journalArticlepeer-review

Abstract

Bullous pemphigoid (BP) constitutes the most frequent autoimmune subepidermal blistering disease. It is associated with autoantibodies directed against the BP antigens 180 (BP180, BPAG2) and BP230 (BPAG1-e). The pathogenicity of anti-BP180 antibodies has been convincingly demonstrated in animal models. The clinical features of BP are extremely polymorphous. The diagnosis of BP critically relies on immunopathologic findings. The recent development of novel enzyme-linked immunosorbent assays has allowed the detection of circulating autoantibodies with relatively high sensitivity and specificity. Although potent topical steroids have emerged in the past decade as first-line treatment of BP, management of the disease may be challenging.

Original languageEnglish
Pages (from-to)3-16
Number of pages14
JournalClinics in Dermatology
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2012

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Bullous pemphigoid: From the clinic to the bench'. Together they form a unique fingerprint.

Cite this